Abstract
We engineered a 21-mer peptide representing amino acids 170-190 of the respiratory syncytial virus (RSV) G protein as a fusion with the Alfalfa mosaic virus (AlMV) coat protein (CP), produced recombinant AlMV particles presenting this peptide (VMR-RSV) on their surfaces and tested the immunogenicity in vitro in human dendritic cells and in vivo in non-human primates. Significant pathogen-specific immune responses were generated in both systems: (i) human dendritic cells armed with VMR-RSV generated vigorous CD4+ and CD8+ T cell responses; (ii) non-human primates that received these particles responded by mounting strong cellular and humoral immune responses. This approach may validate the use of a novel RSV vaccine delivery vehicle in humans.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alfalfa mosaic virus / genetics
-
Animals
-
Antigens, Viral / genetics
-
Base Sequence
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / immunology
-
DNA, Viral / genetics
-
Dendritic Cells / immunology
-
Genetic Vectors
-
Humans
-
In Vitro Techniques
-
Killer Cells, Natural / immunology
-
Macaca fascicularis
-
Macaca mulatta
-
Nicotiana
-
Plants, Genetically Modified
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / prevention & control
-
Respiratory Syncytial Viruses / genetics*
-
Respiratory Syncytial Viruses / immunology*
-
Respiratory Syncytial Viruses / pathogenicity
-
Vaccines, Subunit / genetics
-
Vaccines, Subunit / immunology
-
Vaccines, Subunit / pharmacology
-
Viral Vaccines / genetics*
-
Viral Vaccines / immunology*
-
Viral Vaccines / pharmacology
Substances
-
Antigens, Viral
-
DNA, Viral
-
Vaccines, Subunit
-
Viral Vaccines